|Mr. N. Scott Fine||CEO & Director||479.58k||N/A||1957|
|Dr. Jeffrey L. Tate||COO & Director||252.93k||N/A||1958|
|Dr. Sharon H. Hrynkow||Chief Scientific Officer, Sr. VP of Medical Affairs & Member of Scientific Advisory Board||337.08k||N/A||1960|
|Mr. Joshua M. Fine||CFO & Sec.||N/A||N/A||1982|
|Mr. George L. Fails||Exec. VP and Operations Mang.||N/A||N/A||1945|
|Mr. Michael Eric Lisjak||Chief Regulatory Officer & Sr. VP of Bus. Devel.||N/A||N/A||1973|
|Dr. Gerald F. Cox||Acting Chief Medical Officer||N/A||N/A||1959|
|Mr. Russ Belden||Acting Chief Commercial Officer||N/A||N/A||N/A|
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.
Cyclo Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.